In its observations on South Africa, the UN Committee on the Rights of Persons with Disabilities (UNCRPD) expressed grave concern regarding the rights of people with psychosocial disabilities. Professor Lesley Robertson looks at our medical model of disability and mental health legislation and unpacks the change needed at the societal and health system levels.
Little is known about the number of people in South Africa who are living with rare diseases. In fact, there is no recognised definition for rare disease in the country, contributing to inadequate record-keeping and very little data on prevalence, treatment options, and support structures. Laura Owings reports.
One of the most vibrant areas of HIV research these days is the search for new, more convenient ways to use antiretroviral medicines (ARVs) to prevent HIV infection. Elri Voigt rounds up the HIV pre-exposure prophylaxis (PrEP) research presented at the recent International AIDS Society Conference, including a biodegradable antiretroviral implant.
In 1947 the first black woman qualified as a doctor in South Africa. Her name was Mary Malahlela-Xakana. It took the country about 60 years after its first black male doctor started practicing for Malahlela-Xakana to don her stethoscope and practice medicine. Much, but not enough has changed since then, writes Alicestine October.
The risk of developing severe or fatal COVID-19 is 30% greater in people living with HIV compared to those who are HIV negative, according to a new report from the World Health Organization. Comprised of data from 37 countries, including South Africa, the report suggests people living with HIV should be prioritised for vaccination. Laura Owings reports.
The treatment of drug-resistant forms of tuberculosis has been transformed over the last decade with treatment becoming more effective, safer, and treatment duration in many cases dropping to under a year. Even so, treatment can still come with serious side effects and for some, it can still last over a year and a half. In a finding that may help further reduce side effects, new research has found that the dosage of a key drug can be lowered without compromising how well it works. Tiyese Jeranji and Marcus Low report.
On Monday President Cyril Ramaphosa announced that South Africa will host the first World Health Organization-backed COVID-19 mRNA vaccine Technology Transfer Hub – an initiative designed to get the production of mRNA vaccines off the ground in Africa. Parties involved in the hub expect to hear as early as next week whether pharmaceutical companies with mRNA COVID-vaccines for COVID-19 on the market – Moderna and Pfizer/BioNTech – will share their know-how with the hub. Chris Bateman reports for Spotlight.
Over 30% of those living in South Africa have experienced a depressive, anxiety, or substance use disorder in their lifetime, according to a national survey. Yet studies show only 15% of those with mental health conditions receive treatment. Laura Owings explores what role community healthcare workers can play in addressing this lack of access to care.
Cryptococcal meningitis is the second biggest killer of people living with HIV after tuberculosis (TB). Now, a global initiative, the Ending Cryptococcal Meningitis Deaths by 2030 Strategic Framework aims to get the gold standard drug to treat cryptococcal meningitis – flucytosine – registered in countries that need it. Amy Green reports.
Messenger RNA (mRNA) vaccines, such as the COVID-19 vaccines made by Moderna and Pfizer/BioNTech, have been hailed for their manufacturing advantages over conventional vaccines – so much so that African leaders such as President Cyril Ramaphosa has called for mRNA production capacity to be developed in Africa. Catherine Tomlinson examines why mRNA vaccines are easier to make than some other types of vaccines and asks what it will take to build such production capacity.
With the COVID-19 mass vaccination rollout set to start on 17 May, many more people, for now, those older than 60 years, will receive their jabs. Elri Voigt looked into what, if anything, will change for those who have been vaccinated, and what other countries have done in this regard.
Strict monitoring and surveillance systems for the safety of all vaccines, including those for COVID-19, are in place during vaccine trials as well as once vaccines are rolled out more widely. Adele Baleta takes a look at how vaccine-related adverse events are monitored in South Africa.
